Overview

Corporate Profile

Forward Pharma A/S is a Danish biopharmaceutical company that commenced development in 2005 of FP187®, a proprietary formulation of DMF for the treatment of inflammatory and neurological indications. The Company granted to Biogen an irrevocable license to all of its IP through the Settlement and License Agreement and received from Biogen a non-refundable cash fee of $1.25 billion in February 2017, with the return of EUR 917.7 million to shareholders through a capital reduction in September 2017. The Company has the opportunity to receive royalties from Biogen on sales of Tecfidera® or other DMF products for MS, dependent on, among other things, successfully appealing the U.S. interference and a favorable outcome in Europe with respect to the EP2801355 Opposition Proceedings, including any appeal thereto.


Most Recent Presentation
Download Documentation Corporate Presentation

Stock Information
FWP (Common Stock)
ExchangeNASDAQ GS (US Dollar)
Price$1.45
Change (%) Stock is Down 0.08 (5.23%)
Volume1,165
Data as of 11/12/18 3:09 p.m. ET
Minimum 20 minute delay
Refresh quote
Stock chart for: FWP.OQ.  Currently trading at $1.45 with a 52 week high of $5.70 and a 52 week low of $1.06.

Recent NewsMore >>
DateTitle 
10/24/18Forward Pharma Provides Update on the Decision of the Federal Circuit in its Appeal of the U.S. Patent Interference
The U.S. Court of Appeals for the Federal Circuit has affirmed the decision of the Patent Trial and Appeal Board in the U.S. patent interference proceeding The appeal of the European EP2801355 patent opposition continues Forward expects to reduce operating expenses to match the current situation COPENHAGEN, Denmark, Oct. 24, 2018 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ: FWP) (“Forward” or the “Company”) today announced that the U.S. Court of Appeals for the Federal Circuit (the... 
Printer Friendly Version
09/28/18Forward Pharma to Participate in the Ladenburg Thalmann 2018 Healthcare Conference
COPENHAGEN, Denmark, Sept. 28, 2018 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (the “Company”) today announced that Dr. Claus Bo Svendsen, the Company’s Chief Executive Officer, will participate in the Ladenburg Thalmann 2018 Healthcare Conference in New York, NY. Dr. Svendsen will present a corporate update on Tuesday, October 2, 2018 at 11:30AM ET and will be available for one-on-one meetings. Investors and other interested parties may access a live audio webcast of Dr. Svendsen’s ... 
Printer Friendly Version
09/19/18Forward Pharma Reports Financial and Operational Results from the First Six Months of 2018
COPENHAGEN, Denmark, Sept. 19, 2018 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“We”, “Forward” or the “Company” and together with its subsidiaries, the “Group”), today reported consolidated financial results for the six-month period ended June 30, 2018. Net loss for the six-month period ended June 30, 2018 was $(5.3) million, or $(0.06) per diluted share, versus net income of $941.2 million, or $1.67 per diluted share for the six-month period ended June 30, 2017.  “We are pleased to... 
Printer Friendly Version
08/23/18Forward Pharma to Participate in the LSX Nordic Congress
COPENHAGEN, Denmark, Aug. 23, 2018 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (the “Company”) today announced that Dr. Claus Bo Svendsen, the Company’s Chief Executive Officer, will participate in the LSX Nordic Congress being held August 29-30, 2018 in Stockholm, Sweden. Dr. Svendsen will present a corporate update on Thursday, August 30, 2018 at 15.15 CET and will be available for one-on-one meetings. A recording of the presentation will be made available through the Company’s websi... 
Printer Friendly Version
Upcoming EventsMore >>
There are currently no events scheduled.
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Forward Pharma A/S posts new information to the site. Just enter your e-mail address and click Submit.
 
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources